This week, seven biotechnology stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
Top 10 Oil Companies To Watch For 2015: IXYS Corporation(IXYS)
IXYS Corporation, an integrated semiconductor company, engages in the development, manufacture, and marketing of power semiconductors, advanced mixed signal integrated circuits (ICs), application specific integrated circuits (ASICs), microcontrollers, and systems and radio frequency semiconductors. It offers power metal oxide silicon field effect transistors; insulated gate bipolar transistors; and thyristors and rectifiers, including fast recovery epitaxial diodes. The company?s power semiconductors are used primarily in controlling energy in motor drives; power conversion systems, including switch-mode and uninterruptible power supplies; medical electronics; and renewable energy sources. It also provides ICs, such as solid state relays for telecommunications applications; power management and control ICs comprising current regulators, motion controllers, digital power modulators, and drivers; microcontrollers, including embedded flash microcontrollers, core 8-bit microc ontrollers, and microprocessors; and line card access switch and data access arrangement integrated products. The company?s mixed signal ICs are used in telecommunications products, central office switching equipment, customer premises equipment, set top boxes, remote meter reading equipment, security systems, flat displays, medical electronics, and defense aerospace systems. In addition, it manufactures and sells laser diode drivers, high voltage pulse generators and modulators, high power subsystems/modules/stacks, and direct copper bond substrates. Its radio frequency power devices are used in wireless infrastructure, industrial radio frequency applications, medical systems, and defense and space electronics. It sells its products principally in the United States, Europe and the Middle East, and the Asia Pacific through direct sales personnel, independent representatives, and distributors. IXYS Corporation was founded in 1987 and is headquartered in Milpitas, California.
Advisors' Opinion:- [By Lisa Levin]
IXYS (NASDAQ: IXYS) surged 5.70% to $14.66. The volume of IXYS shares traded was 1097% higher than normal. IXYS' PEG ratio is 0.55.
Posted-In: volume moversNews Intraday Update Markets Movers
Best Tech Companies To Invest In 2014: support.com Inc.(SPRT)
Support.com, Inc. provides online care services for the digital home and small business primarily in North America. Its services and software products install, set up, connect, repair, and protect personal computers (PCs) and related devices that are essential to its customers; and it offers it as one-time services and subscriptions, and as software products to consumers who prefer do-it-yourself solutions. The company?s online care services include installation and setup services; connect and secure services that configure, connect, and establish secure connections between the computer, the wireless network, and supported devices; diagnose and repair services to identify, diagnose, and repair technical problems comprising the removal of viruses, spyware, and other forms of malware; and mobile device services. Its online care services also consist of tune-up services, which optimizes key systems settings for faster start-up and shut-down, loading of programs, and Internet browsing; online data backup; and server and network monitoring and management, hosted email and virtual desktops, and disaster recovery services. In addition, the company offers various software products, such as Advanced Registry Optimizer to identify and repair errors in the registry database on PCs; Cosmos software to maintain and optimize the performance of PCs; Hard Disk Tune-Up that improves the performance of a computer by defragmenting programs and data stored on the hard drive; MemTurbo, which increases available memory and improves PC performance; RapidStart software for removing or delaying unnecessary startup programs, processes, and services; and SUPERAntiSpyware software, an anti-malware technology. It provides its products and services through its channel partners and directly to consumers. The company was formerly known as SupportSoft, Inc. and changed its name to Support.com, Inc. in June 2009. Support.com, Inc. was founded in 1997 and is headquartered in Redwood City, California.
Advisors' Opinion:- [By Steve Symington]
What:�Shares of Support.com (NASDAQ: SPRT ) plunged 26% during intraday trading Thursday after the company beat expectations with its third-quarter results, but outlined disappointing support program changes which will negatively affect its business at Comcast in 2014.
- [By Roberto Pedone]
Support.com (SPRT) is a provider of online care for the digital home and small business. This stock closed up 2.7% to $5.89 in Tuesday's trading session.
Tuesday's Range: $5.67-$5.92
52-Week Range: $3.67-$6.28
Thursday's Volume: 304,000
Three-Month Average Volume: 377,189From a technical perspective, SPRT spiked higher here right above its 50-day moving average of $5.51 with decent upside volume. This move also pushed shares of SPRT into breakout territory, since the stock took out some near-term overhead resistance at $5.80. Shares of SPRT have been uptrending for the last month, with the stock moving higher from its low of $5.01 to its intraday high of $5.92. During that uptrend, shares of SPRT have been consistently making higher lows and higher highs, which is bullish technical price action.
Traders should now look for long-biased trades in SPRT as long as it's trending above its 50-day at $5.51 or above more near-term support at $5.43 and then once it sustains a move or close above Tuesday's high of $5.92 to its 52-week high at $6.28 with volume that hits near or above 377,189 shares. If that breakout triggers soon, then SPRT will set up to enter new 52-week-high territory above $6.28, which is bullish technical price action. Some possible upside targets off that move are $7 to $8.
Best Tech Companies To Invest In 2014: Sucampo Pharmaceuticals Inc (SCMP)
Sucampo Pharmaceuticals, Inc., incorporated on December 9, 2008, is a global biopharmaceutical company focused on research, discovery, development and commercialization of drugs based on ion channel activators known as prostones. The Company�� prostone-based compounds target the ClC-2 and big potassium (BK), ion channels. It is focused on developing prostones to treat gastrointestinal, ophthalmic, neurologic, and oncology-based inflammatory disorders, and is also considering other therapeutic applications of its drug technology. The Company�� products include AMITIZA (lubiprostone) and RESCULA (unoprostone isopropyl).
AMITIZA
The Company�� AMITIZA is being marketed in the United States for three gastrointestinal indications under a license agreement, or the Takeda Agreement, with Takeda Pharmaceutical Company Limited, or Takeda. The three gastrointestinal indications include chronic idiopathic constipation (CIC), in adults, irritable bowel syndrome with constipation (IBS-C), in adult women, and opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain. AMITIZA for OIC received approval from the United States Food and Drug Administration (FDA), in April 2013. In Japan, AMITIZA is marketed under a license, commercialization and supply agreement, or the Abbott Agreement, with Abbott Japan Co. Ltd. (Abbott), for the gastrointestinal indication of chronic constipation (CC), excluding constipation caused by organic diseases. In Switzerland, the Company is marketing AMITIZA.
RESCULA
The Company holds license agreements for RESCULA in the United States and Canada and the rest of the world, with the exception of Japan, Korea, Taiwan and the People�� Republic of China. The Company is commercializing RESCULA (unoprostone isopropyl ophthalmic solution) 0.15% for the lowering of intraocular pressure (IOP), in patients with open-angle glaucoma or ocular hypertension in the United States. RESCULA may be used as an agent or concomit! antly with other topical ophthalmic drug products to lower intraocular pressure. RESCULA is a BK channel activator and has a different mechanism of action than other IOP lowering agents on the market.
Advisors' Opinion:- [By James Brumley]
Still, for the nimble who know when to get out, OREX is one of the few cheap stocks worth a closer look.
Sucampo Pharmaceuticals (SCMP)Finally, though the price of $7.60 clearly qualifies it as one pf the cheapest of the cheap stocks out there in the pharmaceutical world, that’s not the reason Sucampo Pharmaceuticals (SCMP) may be worth a look here. It’s the 30% slide we’ve seen SCMP stock suffer since peaking in mid-January. It’s not a pullback that’s bound to go unchallenged by the bulls.
Best Tech Companies To Invest In 2014: Cyan Inc (CYNI)
Cyan, Inc., incorporated on October 25, 2006, has carrier-grade networking solutions that transform legacy networks into open, high-performance networks. The Company�� solutions include high-capacity, multi-layer switching and transport platforms, as well as a carrier-grade software-defined networking platform and applications. The Company�� solutions enable network operators to virtualize their networks, accelerate service delivery. The Company has designed its solutions to provide a range of applications, including business Ethernet, Wireless and broadband support services and cloud connectivity. The Company also offer high-capacity, multi-layer switching and transport platforms, known as its Cyan Z-Series, that have been designed to support the multiple concurrent technologies used in regional and metro networks, including both Ethernet-based services, as well as optical services.
The Company�� Z-Series platforms have been designed to transport traffic over network layer, utilizing both electrical and optical domains, to enable network operators to maximize network capacity at the lowest cost per bit. The Company�� customers range from service providers to high-performance data center and large, private network operators.
Advisors' Opinion:- [By Lauren Pollock]
Among the companies with shares expected to actively trade in Tuesday’s session are Cyan Inc.(CYNI), Neurocrine Biosciences Inc.(NBIX) and SandRidge Energy Inc.(SD)
Best Tech Companies To Invest In 2014: Amdocs Limited (DOX)
Amdocs Limited, together with its subsidiaries, provides software and services for communications, media, and entertainment industry service providers worldwide. It offers revenue management products, including convergent charging and billing, mediation, partner management, service delivery, compact convergence, and machine-to-machine solutions that manage the end-to-end network services revenue stream from offer definition to cash-in-hand and spans the consumer, business, and partner domains. The company also provides customer management products comprising multichannel selling, multichannel care, and proactive insight products that enable service providers to simplify the customer experience in all interaction channels and touch points; operations support systems, such as network planning, service fulfillment, service assurance, inventory and discovery, business service capture, network navigator, and radio parameter manager for fixed line, wireless, and cable networks; and network control products consisting of service controllers, home subscriber servers, policy controllers, data and Wi-Fi experience solutions, and intelligent diameter routing agents. In addition, it offers digital services, which include connected home solutions, mobile payments, digital commerce solutions, personalization, and unified communications and foundation. Further, the company provides advertising and media solutions that comprise sales experience, business agility, small-medium business experience, and business content and advertising syndication solutions. Additionally, it offers business consulting, system integration, information technology outsourcing and value process operation managed services, managed transformation, and product support services. Amdocs Limited was founded in 1988 and is based in St. Peter Port, Channel Islands.
Advisors' Opinion:- [By Omar Venerio]
The company has a current ROE of 19.09%, which is higher than the industry median and the ones exhibited by CGI Group (GIB) and Amdocs (DOX). In general, analysts consider ROE ratios in the 15-20% range as representing attractive levels for investment. So for investors looking those levels or more, Teradata (TDC) could be the option. For more attractive ROE, Gartner (IT) and Igate (IGTE) have extremely good ratios. It is very important to understand this metric before investing and it is important to look at the trend in ROE over time.
Best Tech Companies To Invest In 2014: Amgen Inc.(AMGN)
Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada. The company markets recombinant protein therapeutics in supportive cancer care, nephrology, and inflammation. Its principal products include Aranesp and EPOGEN erythropoietic-stimulating agents that stimulate the production of red blood cells; Neulasta and NEUPOGEN to stimulate the production of neutrophils, which is a type of white blood cell that helps the body to fight infections; and Enbrel, an inhibitor of tumor necrosis factor that plays a role in the body?s response to inflammatory diseases. The company also markets other products comprising Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin (TPO) receptor agonist that mimics endogenous TPO, the primary driver of platelet production. In addition, it provides Denosumab, a human monoclonal antibody that targets RANKL, an essential regulator of osteoclasts. Further, the company offers product candidates in mid-to-late stage development in a variety of therapeutic areas, including oncology, hematology, inflammation, bone, nephrology, cardiovascular, and general medicine consisting of neurology. It markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and wholesale distributors of pharmaceutical products. The company has various collaborative arrangements with Pfizer Inc.; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Daiichi Sankyo Company, Limited; Array BioPharma Inc.; Kyowa Hakko Kirin Co. Ltd.; and Cytokinetics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Advisors' Opinion:- [By Maxx Chatsko]
Intellectual property laws today allow a company 20 years of patent protection from the date of filing. That's a bit different from the former laws that granted 17 years of protection from the date of issuance from the U.S. Patent and Trademark Office. Depending on how quickly an application moves through the office, a company today could enjoy an extra year or two of protection compared to the previous precedent. Unless, of course, you are Amgen� (NASDAQ: AMGN ) .
- [By Johanna Bennett]
Schoenebaum also writes that today�� study results bode well for other typed of cholesterol-lowering drugs now in R&D pipelines, namely the PCKSK9 inhibitors being developed by Amgen (AMGN), Regeneron Pharmaceuticals (REGN) and Pfizer (PFE).
- [By Ben Levisohn]
Biotech stocks aren’t falling much today, however. The iShares Nasdaq Biotechnology ETF has dropped 0.5% to $254.31, while Biogen Idec (BIIB) is off 0.3% to $335.85 and Amgen (AMGN) and Regeneron Pharmaceuticals (REGN) are little changes at $122.25 and $304.41, respectively.
- [By Ben Levisohn]
Who’d have thunk it? After lagging for much of the year, Gilead Sciences (GILD) is now outperforming the other big biotech stocks like Amgen (AMGN) and Biogen Idec (BIIB).
No comments:
Post a Comment